Liquid Biopsy Market is projected to surpass US$ 3.4 Billion by 2024
For more Info: https://www.renub.com/global-liquid-biopsy-market-nd.php Liquid Biopsy is a non-invasive technology which is used in the detection of molecular biomarkers without the need for invasive or costly surgical procedures. Liquid Biopsy is a simple and an alternative method to surgical biopsies which helps physicians to discover a range of information about a tumor or a disease through a simple blood, urine, saliva or cerebrospinal fluids sample. Circulating cancer cells or traces of the cancer’s DNA or DNA in the fluid sample can give indication about the treatments that a patient likely to need. Liquid Biopsy Market is projected to surpass US$ 3.4 Billion by the end of year 2024. Request a free sample copy of the report: https://www.renub.com/contactus.php Increasing Cancer Incidences On an estimate nearly 14.1 million people suffered from cancer around the world in 2012, of which 7.4 million were men and 6.7 million women. The incidence of cancer seems to be increasing with increasing per capita income. Asia, Europe and Americas are some of the regions where highest incidences of cancer occur. Lung Cancer, Colorectal Cancer and Breast Cancer are among the most prevalent types of cancer worldwide. Client can Purchase this Report in Sections from below link: Access full Research: https://www.renub.com/liquid-biopsy-market-p.php Due to the rising prevalence of cancer and the complexity of cancer’s treatment, demand for liquid biopsy test is increasing more rapidly during the patient’s care than ever before. The liquid biopsy test is basically the analysis of various analytes, namely Circulating Tumor Cells (CTCs), Circulating Tumor DNA (ctDNA), Extracellular Vesicles (Exosomes), miRNA, mRNA and Proteins. Circulating Tumor Cells (CTCs) and Circulating Tumor DNA (ctDNA) have been the most analyzed and commercially developed medical technologies amongst these analytes.
190 views • 14 slides
